<p>IFP Advisors Inc 在最近向证券交易委员会（SEC）披露的文件中表示，在第二季度将其在 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免费报告）中的持股减少了 47.3%。该公司在此期间出售了 76,563 股后，持有 85,358 股该公司的股票。IFP Advisors Inc 在最近一个季度末持有的 Orchestra BioMed 股票约占 0.22%，价值 229,000 美元。</p>
<p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>其他一些对冲基金也增加或减少了对该公司的投资。Nuveen LLC 在第一季度新购入了价值约 179,000 美元的 Orchestra BioMed 股票。德意志银行在第一季度将其在 Orchestra BioMed 的持股增加了 67.3%。德意志银行目前持有 20,219 股该公司的股票，价值 87,000 美元，此前在上个季度又购买了 8,134 股。最后，美国银行在第四季度将其在 Orchestra BioMed 的持股提高了 42.0%。美国银行目前持有 23,780 股该公司的股票，价值 95,000 美元，此前在上个季度又购买了 7,036 股。目前，53.20% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些研究公司最近对 OBIO 发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 Orchestra BioMed 股票的 &#34;卖出（e+）&#34;评级。HC Wainwright 在 9 月 4 日的研究报告中将 Orchestra BioMed 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予了 &#34;买入&#34;评级。Chardan Capital 在 8 月 13 日的报告中重申了 &#34;买入&#34;评级，并将 Orchestra BioMed 股票的目标价设定为 20.00 美元。最后，BTIG Research 在 8 月 20 日的研究报告中重申了对 Orchestra BioMed 股票的 &#34;中性&#34;评级。一位研究分析师对该股票给予了强烈买入评级，三位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 13.50 美元。</p>
<p><strong>查看我们最新的 OBIO 股票分析</strong></p>
<h2>内部人士买卖</h2>
<p>在其他 Orchestra BioMed 的新闻中，内部人士 David P. Hochman 在 8 月 4 日的交易中购买了 20,000 股该公司的股票。该股票的平均购买价格为每股 2.75 美元，总交易额为 55,000.00 美元。交易完成后，内部人士直接持有 349,331 股该公司的股票，价值 960,660.25 美元。这笔交易代表了他们持股的 6.07% 增加。该收购在向 SEC 的文件中披露，可以通过此超链接访问。内部人士在上个季度购买了价值 100,384 美元的 37,760 股公司股票。8.10% 的股票由公司内部人士持有。</p>
<h2>Orchestra BioMed 股票上涨 0.5%</h2>
<p>NASDAQ OBIO 周五开盘价为 3.68 美元。该公司的 50 日移动平均线为 2.71 美元，200 日移动平均线为 2.85 美元。该公司的债务与股本比率为 48.76，流动比率为 2.10，速动比率为 2.09。该股票的市值为 1.422 亿美元，市盈率为 -2.01，贝塔值为 0.60。Orchestra BioMed Holdings, Inc. 的一年低点为 2.20 美元，一年高点为 6.50 美元。</p>
<p>Orchestra BioMed（NASDAQ:OBIO - 获取免费报告）最近在 8 月 12 日发布了其财报。该公司报告本季度每股收益为（0.50）美元，超出分析师的共识预期（0.51）美元 0.01 美元。Orchestra BioMed 的净利润率为 -2,367.49%，股本回报率为 -289.42%。该公司本季度的收入为 84 万美元，而分析师的预期为 78 万美元。股票研究分析师预测，Orchestra BioMed Holdings, Inc. 本年度将发布 -1.66 的每股收益。</p>
<h2>Orchestra BioMed 公司简介</h2>
<p>（免费报告）</p>
<p>Orchestra BioMed Holdings, Inc. 是一家生物医学创新公司。该公司的旗舰产品候选包括用于治疗高血压（HTN）的 BackBeat 心脏神经调节疗法（CNT）；以及用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus AngioInfusion Balloon（SAB）。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Orchestra BioMed 更好</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>Salesforce 期待已久的拐点来了：反弹开始！</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Rocket Lab USA 获得华尔街的认可：现在是买入时机吗？</li>
<li>在哪里可以找到财报电话会议的记录</li>
<li>Archer 收购竞争对手的专利宝藏，进行战略性举措</li>
</ul>
<p><strong>想看看其他对冲基金持有 OBIO 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Orchestra BioMed 吗？</h2>
<p>在考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Orchestra BioMed 并不在名单上。</p>
<p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

OBIO

<p>IFP Advisors Inc 在第二季度减少了对 Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) 的持股比例，降幅为 47.3%，目前持有 85,358 股，价值 229,000 美元。其他对冲基金也调整了他们的持仓。分析师对 OBIO 的评级不一，平均目标价为 13.50 美元。内部人士 David P. Hochman 最近购买了 20,000 股。该股票目前交易价格为 3.68 美元，市值为 1.422 亿美元，上一季度的每股收益为-0.50 美元</p>

<p>IFP Advisors Inc lowered its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 47.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,358 shares of the company's stock after selling 76,563 shares during the period. IFP Advisors Inc owned approximately 0.22% of Orchestra BioMed worth $229,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>IFP Advisors Inc 在最近向证券交易委员会（SEC）披露的文件中表示，在第二季度将其在 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免费报告）中的持股减少了 47.3%。该公司在此期间出售了 76,563 股后，持有 85,358 股该公司的股票。IFP Advisors Inc 在最近一个季度末持有的 Orchestra BioMed 股票约占 0.22%，价值 229,000 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen LLC acquired a new position in shares of Orchestra BioMed during the first quarter worth approximately $179,000. Deutsche Bank AG increased its stake in Orchestra BioMed by 67.3% during the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company's stock worth $95,000 after buying an additional 7,036 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也增加或减少了对该公司的投资。Nuveen LLC 在第一季度新购入了价值约 179,000 美元的 Orchestra BioMed 股票。德意志银行在第一季度将其在 Orchestra BioMed 的持股增加了 67.3%。德意志银行目前持有 20,219 股该公司的股票，价值 87,000 美元，此前在上个季度又购买了 8,134 股。最后，美国银行在第四季度将其在 Orchestra BioMed 的持股提高了 42.0%。美国银行目前持有 23,780 股该公司的股票，价值 95,000 美元，此前在上个季度又购买了 7,036 股。目前，53.20% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research firms have recently weighed in on OBIO. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright dropped their price objective on Orchestra BioMed from $12.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, September 4th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Wednesday, August 13th. Finally, BTIG Research reiterated a &#34;neutral&#34; rating on shares of Orchestra BioMed in a research note on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $13.50.</p>
<div class="lb-trans"><p>一些研究公司最近对 OBIO 发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 Orchestra BioMed 股票的 &#34;卖出（e+）&#34;评级。HC Wainwright 在 9 月 4 日的研究报告中将 Orchestra BioMed 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予了 &#34;买入&#34;评级。Chardan Capital 在 8 月 13 日的报告中重申了 &#34;买入&#34;评级，并将 Orchestra BioMed 股票的目标价设定为 20.00 美元。最后，BTIG Research 在 8 月 20 日的研究报告中重申了对 Orchestra BioMed 股票的 &#34;中性&#34;评级。一位研究分析师对该股票给予了强烈买入评级，三位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 13.50 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 OBIO 股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Orchestra BioMed news, insider David P. Hochman bought 20,000 shares of the business's stock in a transaction on Monday, August 4th. The stock was purchased at an average price of $2.75 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the insider directly owned 349,331 shares of the company's stock, valued at $960,660.25. This trade represents a 6.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought 37,760 shares of company stock worth $100,384 over the last quarter. 8.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Orchestra BioMed 的新闻中，内部人士 David P. Hochman 在 8 月 4 日的交易中购买了 20,000 股该公司的股票。该股票的平均购买价格为每股 2.75 美元，总交易额为 55,000.00 美元。交易完成后，内部人士直接持有 349,331 股该公司的股票，价值 960,660.25 美元。这笔交易代表了他们持股的 6.07% 增加。该收购在向 SEC 的文件中披露，可以通过此超链接访问。内部人士在上个季度购买了价值 100,384 美元的 37,760 股公司股票。8.10% 的股票由公司内部人士持有。</p>
</div><h2>Orchestra BioMed Trading Up 0.5%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上涨 0.5%</h2>
</div><p>NASDAQ OBIO opened at $3.68 on Friday. The business's fifty day moving average is $2.71 and its 200-day moving average is $2.85. The company has a debt-to-equity ratio of 48.76, a current ratio of 2.10 and a quick ratio of 2.09. The stock has a market capitalization of $142.20 million, a price-to-earnings ratio of -2.01 and a beta of 0.60. Orchestra BioMed Holdings, Inc. has a one year low of $2.20 and a one year high of $6.50.</p>
<div class="lb-trans"><p>NASDAQ OBIO 周五开盘价为 3.68 美元。该公司的 50 日移动平均线为 2.71 美元，200 日移动平均线为 2.85 美元。该公司的债务与股本比率为 48.76，流动比率为 2.10，速动比率为 2.09。该股票的市值为 1.422 亿美元，市盈率为 -2.01，贝塔值为 0.60。Orchestra BioMed Holdings, Inc. 的一年低点为 2.20 美元，一年高点为 6.50 美元。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01. Orchestra BioMed had a negative net margin of 2,367.49% and a negative return on equity of 289.42%. The firm had revenue of $0.84 million for the quarter, compared to analysts' expectations of $0.78 million. Equities research analysts predict that Orchestra BioMed Holdings, Inc. will post -1.66 EPS for the current year.</p>
<div class="lb-trans"><p>Orchestra BioMed（NASDAQ:OBIO - 获取免费报告）最近在 8 月 12 日发布了其财报。该公司报告本季度每股收益为（0.50）美元，超出分析师的共识预期（0.51）美元 0.01 美元。Orchestra BioMed 的净利润率为 -2,367.49%，股本回报率为 -289.42%。该公司本季度的收入为 84 万美元，而分析师的预期为 78 万美元。股票研究分析师预测，Orchestra BioMed Holdings, Inc. 本年度将发布 -1.66 的每股收益。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc. 是一家生物医学创新公司。该公司的旗舰产品候选包括用于治疗高血压（HTN）的 BackBeat 心脏神经调节疗法（CNT）；以及用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus AngioInfusion Balloon（SAB）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Orchestra BioMed 更好</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>Salesforce 期待已久的拐点来了：反弹开始！</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Rocket Lab USA 获得华尔街的认可：现在是买入时机吗？</li>
<li>在哪里可以找到财报电话会议的记录</li>
<li>Archer 收购竞争对手的专利宝藏，进行战略性举措</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OBIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 OBIO 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Orchestra BioMed 吗？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Orchestra BioMed 并不在名单上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

IFP Advisors Inc 在 Orchestra BioMed Holdings, Inc. $OBIO 中持有 22.9 万美元的头寸